.Attribute Medicine, Released online: 16 September 2024 doi:10.1038/ s41591-024-03244-8In the observational SCRUM-Japan GOZILA research study, after a typical consequence of 11 months, patients along with metastatic intestinal lumps who got biomarker-matched treatments based upon circulating cyst DNA profiling showed a higher scientific advantage than those getting unparalleled treatment.